ArticleInternational journal of clinical and experimental pathology2018
miR-761 inhibits human osteosarcoma progression by targeting CXCR1.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Suppression of MIR31HG affects the functional properties of thyroid cancer cells depending on the miR-761/MAPK1 axis.BMC endocrine disorders · 2022Article
- Long noncoding RNA ADIRF antisense RNA 1 upregulates insulin receptor substrate 1 to decrease the aggressiveness of osteosarcoma by sponging microRNA-761.Bioengineered · 2022Article
- Long non-coding RNA PCED1B antisense RNA 1 promotes gastric cancer progression via modulating microRNA-215-3p / C-X-C motif chemokine receptor 1 axis.Bioengineered · 2021Article
- LncRNA TPTEP1 inhibited the proliferation and metastasis of non-small cell lung cancer cells by targeting miR-761/LATS2 axis.American journal of translational research · 2021Article
- lncRNA-TINCR Functions as a Competitive Endogenous RNA to Regulate the Migration of Mesenchymal Stem Cells by Sponging miR-761.BioMed research international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
microRNAs (miRs) are endogenous noncoding RNAs that participate in a variety of cellular processes by regulating multiple targets to promote or inhibit cell behaviors. Emerging evidence suggests that miR-761 plays important roles in human cancers to function as either a tumor suppressor gene or an oncogene. However, its biological role in osteosarcoma (OS) remains largely elusive. This study found the expression of miR-761 was significantly reduced in OS tissues and cell lines. CXC receptor-1 (CXCR1), an oncogene which was overexpressed in a variety of human cancers including OS, was identified as a novel target of miR-761 using bioinformatic, luciferase reporter, and western blot analyses. Cell function assays revealed that miR-761 could inhibit cell proliferation and invasion at least partially through targeting CXCR1. Collectively, our present study suggested that miR-761 may be a promising treatment biomarker for OS.
Indexed as
Identifiers
31949613PMC6963019What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.